ENTA News and Press, Enanta Pharmaceuticals Inc. From 01/06/23

Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023 Presents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission Expands Robust COVID-19 Antiviral Portfolio...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Confere...

Summary The market's punishment of Enanta Pharmaceuticals, Inc. during FY22 has been quite heavy. Despite two attempted snap-back rallies, Enanta Pharmaceuticals stock was rejected at resistance levels on each attempt. The macro-landscape has created a more challenging funding envir...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast...

Initiated SPRINT ( S ARS-Cov-2 PR otease IN hibitor T reatment), a Phase 2 Study of EDP-235, an Oral, 3CL Protease Inhibitor, in Non-Hospitalized, Symptomatic Patients With Mild to Moderate COVID-19 Initiated RSVHR, a Phase 2 Study of EDP-938, an Oral N-Prote...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2022 aft...

Enanta Pharmaceuticals ( NASDAQ: ENTA ) said it started a phase 2 trial of its oral drug EDP-235 to treat non-hospitalized, symptomatic adults with mild or moderate COVID-19. The study, dubbed SPRINT, will evaluate the safety, tolerability and antiviral activity o...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the initiation of SPRINT ( S ARS-Cov-2 PR otease IN hibitor T reatment), a Phase 2 clinical trial of E...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting the potential of EDP-235 for the treatment of COVID-19, which are b...

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-prote...